. Postpartum haemorrhage (PPH) is a potentially life-threatening Background complication for women, and the leading cause of maternal mortality. Tranexamic acid (TXA) is an antifibrinolytic used worldwide to treat uterine haemorrhage and to reduce blood loss in general surgery. TXA may have effects on thrombin generation, platelet function and coagulation factors as a result of its inhibition on the plasmin.
Abstract
. Postpartum haemorrhage (PPH) is a potentially life-threatening Background complication for women, and the leading cause of maternal mortality. Tranexamic acid (TXA) is an antifibrinolytic used worldwide to treat uterine haemorrhage and to reduce blood loss in general surgery. TXA may have effects on thrombin generation, platelet function and coagulation factors as a result of its inhibition on the plasmin.
. WOMAN ETAPlaT is a sub-study of the World Maternal Methods Antifibrinolitic trial (WOMAN trial). All adult women clinically diagnosed with PPH after a vaginal delivery or caesarean section, are eligible for inclusion in the study. Blood samples will be collected at the baseline and 30 minutes after the first dose of study treatment is given. Platelet function will be evaluated in whole blood immediately after sampling with Multiplate® tests (ADPtest and TRAPtest). Thrombin generation, fibrinogen, D-dimer, and coagulation factors vW, V and VIII will be analysed using platelet poor plasma.
Recruitment to WOMAN ETAPlaT started on 04 November 2013 and Results. closed on 13 January 2015, during this time 188 patients were recruited. The final participant follow-up was completed on 04 March 2015. This article introduces the statistical analysis plan for the study, without reference to unblinded data.
The data from this study will provide evidence for the effect of Conclusion. TXA on thrombin generation, platelet function and coagulation factors in women with PPH. Referee Status: 
Preface
The purpose of the statistical analysis plan (SAP) is to ensure the credibility of the study findings by pre-specifying the statistical approaches to the analysis of the study data prior to hard locking the database and unblinding of the WOMAN ETAPlaT trial data. To prevent outcome bias and selective reporting, a detailed SAP is presented in order to avoid post hoc decisions that may influence the interpretation of the results and the statistical analyses of the final data.
This SAP is a technical extension of the WOMAN ETAPlaT study protocol (Version 1.1, dated August 29, 2014), which is published elsewhere (Dallaku et al., 2016) . The SAP follows the principles of the International Conference on Harmonization (ICH) guidelines E3, E6 and E9 (ICH, 2016) .
Study objectives and endpoints of WOMAN-ETAPlaT
Objectives of the study Primary objectives: This study will assess if TXA, by inhibiting the plasmin, has an effect on decrease over time on the continuous response variable, thrombin generation assay (TGA) parameter: endogenous thrombin potential (ETP). Secondary objectives: evaluation of the effect of TXA on women with PPH, through monitoring the platelet function (multiplate analyser), plasmatic levels of fibrinogen, D-dimer, coagulation factor V (FV), coagulation factor VIII (FVIII), coagulation factor von Willebrandt (vWF) and other TGA parameters: lag time (LT), time to peak (TtP), and peak height (Ph).
Endpoints Primary efficacy endpoint. The primary efficacy endpoint is the TGA parameter -ETP (nM/minute). Values of ETP will be measured in venous blood samples. Blood samples will be collected at the baseline and at 30 ±15 minutes after the first dose of study treatment is given. Analysis will be performed on processed, separated platelet poor plasma, and preserved in deep freeze, as described in the ETAPlaT protocol (Dallaku et al., 2016) .
Secondary efficacy endpoints. Secondary outcomes will include parameters measuring the effect of TXA on other TGA parameters (LT, TtP, and Ph -we will transform variables prior to analysis if there is evidence that distributions are skewed), fibrinogen, D-dimer and coagulation factors V, VIII, vWF (measured on processed plasma samples as described on primary endpoint) and platelet function analysed by Multiplate ® tests (ADPTest, TRAPTest -measured on whole blood).
Study methods

Study design
The WOMAN-ETAPlaT is a sub-study of the WOMAN trial, an international randomised, double blinded, placebo-controlled trial. The ETAPlaT sub-study has the same study design as the WOMAN trial, but includes some additional laboratory tests. Women who fulfil the eligibility criteria for the WOMAN trial, including adult women clinically diagnosed with primary PPH after a vaginal delivery (>500 ml blood loss), a caesarean delivery (>1000 mL blood loss), or enough blood loss to compromise the haemodynamic status will be randomized. Regarding exclusion criteria, will not be randomized those women with PPH for whom the physician believes there is an indication or contraindication to use TXA.
Immediately after randomization, women will receive the trial treatment by i/v administration of either TXA (1 gram) or placebo (NaCl solution 0.9%). If after 30 minutes the haemorrhage continues or if it stops and restarts within 24 hours after randomization, a second dose may be given. This second dose is not relevant for the current sub-study.
Randomisation, blinding and ethics approval
Packs with study drugs were prepared according to the randomization list, generated by an independent statistician. The active study drug (TXA) and placebo (NaCl 0.9%) will be identical in appearance, and randomization number will be used for identification of packs. Each box has eight packs of study drugs, and the lowest number pack will be used first. After completing the consent procedure, eligible patients are randomized to receive either TXA or placebo. Both the patients and the medical representatives participating in the study are masked to the treatment distribution. Ethical approval was obtained in July 11, 2013 by National Ethics Committee in Tirana, Albania (ref. 62 and 81) Study variables and study schema Details concerning the baseline (treatment) and follow-up (post treatment) period together with the frequency and timing of relevant variables or assessments are displayed at Table 1 .
Sample size
The sample size calculation is focused on the first component of the primary endpoint: change over time of ETP in women with PPH. In a previous study (McLean et al., 2012) ETP in patients with term pregnancy, within each subject group, was normally distributed with a mean of 2410 nM/min and standard deviation (SD) of 543 nM/min.
Assuming a correlation of 0.6 between two time points, the standard deviation of the change can be calculated as 485 {sqrt[2×543^2×(1-0.6)])}. We assume a decrease in ETP of 10% (243 nM/min) over time in the TXA group and no change in the placebo group. To detect an ETP difference of 243 nM/min between groups at a 5% significance level with a power of 80%, two groups each with 88 patients are needed.
A correlation of 0.6 is seen as a conservative estimate as the within individual changes in TGA over time is strictly controlled, which implies a high correlation between time points.
General considerations
Timing of analyses Participant recruitment started on 4 November 2013 and was completed on 13 January 2015. The final participant follow-up was completed on 04 March 2015.
All final analyses will be performed on the database at LSHTM (London, UK) which consists of several tables (Table 1) . After documenting all data collection forms (DCF) data, data cleaning and query resolution, the following prerequisites for unblinding must be fulfilled: the resolution of all queries concerning DCF and laboratory results, and the finalisation of the SAP document.
All these processes before database locking must take place to comply with requirements.
Following data integrity checks the database will be locked after October 2016 and the statistical analysis specified in the SAP and approved by the Trial Steering Committee (TSC), will be performed in advance of the WOMAN trial database lock. In the event the TSC approves analysis before the end of the WOMAN trial, only the independent Data Monitoring Committee (DMC) statistician will be aware of each participant's treatment allocation. Each participant will be allocated a unique identifier (different from that of the WOMAN trial before unblinding). This is to ensure that the WOMAN trial blinding is not compromised in any way.
Analysis populations Full analysis set (FAS).
The primary efficacy analysis follows the principle of intention to treat (ITT), which implies that study data are analysed based on the original allocation of patients, regardless of a treatment received. Withdrawals, participants lost to follow-up and participants who did not adhere fully to the WOMAN ETAPlaT study protocol, will not be excluded from the primary efficacy analyses provided that they satisfy major entry criteria. Also, a patient will be included in the primary efficacy analysis if only the baseline measurement is available.
Per-protocol set (PP). The PP set consists of all patients who did not substantially deviate from the WOMAN ETAPlaT protocol as to be determined on a per-subject basis. The PP set of subjects defining a subset of the FAS is characterised as follows. Covariates and subgroups There exists no a priori hypothesis of subgroup differences. Hence, no pre-planned confirmatory subgroup analyses will be performed to explore evidence for a difference in treatment effects (interaction effect).
Exploratory subgroup-specific summary statistics will be reported for main causes of PPH (uterine atony, placenta previa or abruption and genital trauma), the severity of PPH (moderate-severe PPH), platelet count, fibrinogen level, preeclampsia, chorioamionitis and prematurity (see exploratory subgroup analysis).
Summary of study data
All continuous variables will be summarised by treatment group (TXA/placebo) using the following descriptive statistics: sample size (N), mean ±standard deviation (SD), median, maximum and minimum. The absolute frequency and percentages of observed levels will be reported for all categorical variables. Summary statistics will be displayed overall and stratified by the treatment group. If considered appropriate these data are summarised by centre as well. The key baseline characteristics selected are presented in Table 2 .
Baseline characteristics
In a study about the mode of anaesthesia related to PPH after caesarean deliveries, a significantly higher amount of blood loss during general anaesthesia compared to spinal anaesthesia was previously reported (Aksoy et al., 2015) . The reduction of blood loss in neuroaxial anaesthesia maybe was caused partly from hypotension and by fluids infused in these women (Heesen et al., 2013) . Another role in increased blood loss during general anaesthesia was reported from volatile anaesthetics which may decrease the myometrium contractility (Yoo et al., 2006) and as result can cause uterine atony. Also, volatile anaesthetics with their inhibition effect on platelet aggregation (Yuki et al., 2013) can increase the risk for PPH. precision (95% CI). In analysis of the primary outcome(TGA-ETP), the TXA group will be compared with the placebo group, based on analysis of covariance (ANCOVA) which adjusts for the length of time between two measurements (30±15 minutes) of the baseline and follow-up TGA -ETP value (Table 3) . Primary outcome will be analysed also according to the underlying cause of PPH (uterine atony, placenta previa, placental abruption, and genital trauma) in correlation to TXA/placebo.
Effect of TXA on thrombin generation
There is no evidence about evaluation of TXA effect on thrombin generation in women with PPH. In a systematic review Valentino & Holme (2015) analysed studies about the combined administration of TXA with an anti-inhibitor coagulant complex (AICC) in haemophilia patients. The clot stability and coagulation state measured with thromboelastography and thrombin generation assay respectively, resulted with an increase of maximum clot firmness without an increase in ETP. Although it is known that AICC enhances thrombin generation, combined treatment of TXA with AICC improved the clot stability without enhancing the thrombin generation.
In patients receiving combined therapy of TXA and activated prothrombin complex concentrate (APCC), thrombin generation was lower than in healthy controls (Holmstrom et al., 2012) . We can assume that the main effect in decreasing the thrombin generation is by TXA, since APCC as monotherapy is known to increase thrombin generation. TXA effect to decrease the thrombin generation was confirmed also by Tran et al. (2014) evaluating combined therapy of APCC and TXA, which resulted without a significant increase of thrombin generation compared with healthy controls. The ETP measured in platelet poor plasma was greater in monotherapy of recombinant activated factor VII (rFVIIa) compared with combined treatment of rFVIIa and TXA. Thrombin generation was decreased by TXA also in combined treatment with rFVIIa.
Thrombin generation was increased when plasmin was added to normal plasma samples, and ETP peak height were significantly increased compared to plasmin absence (Ogiwara et al., 2010) . TXA administered in women diagnosed with PPH can decrease the thrombin generation by inhibiting plasmin.
Efficacy analyses of secondary outcomes
The same analyses as for primary outcome will be performed for the blood parameters which are secondary endpoint parameters of Multiplate © tests (ADPtest and TRAPtest), fibrinogen, D-dimer, Dionne et al. (2015) mentioned that prolonged second stage labour was associated with increased risk and severity of PPH. Other potential risk factors for PPH were null-parity, high birthweight and antepartum anaemia, where low levels of haemoglobin before delivery were associated with a low efficacy of haemostasis mechanism promoted by red cells and platelets (Biguzzi et al., 2012) , and as result with an increased risk for PPH.
Efficacy analyses of primary outcome
Both groups of randomised patients, those allocated to the TXA group and placebo group will be compared and analysed on an intention-to-treat basis, irrespective of treatment given. The results will be presented as appropriate effect estimates with a measure of coagulation factors V, VIII, vWF and other TGA parameters (lag time, time to peak, peak height) ( Table 4) . The results will be presented as appropriate effect estimates with a measure of precision (95% CI).
The remaining secondary outcomes will be analysed using appropriate regression models such as Cox model, Poisson or logistic regression (mortality, surgical interventions, blood transfusions, thromboembolic events) and t-tests. The influence of any coagulation disease and anticoagulation treatment/prophylaxis on the TXA effect for blood parameters under study will be assessed. A further sensitivity analysis will be done by adjusting for the amount of blood loss prior to randomisation. All statistical analyses will be conducted with the statistics package R and STATA.
Exploratory subgroup analyses
The influence of any concomitant diseases of pregnancy (preeclampsia, prematurity and chorioamnionitis), or PPH primary causes (uterine atony, placenta previa or abruption and genital tract trauma) on the TXA effect on the blood parameters under study will be assessed. Similar tables will be provided for the subgroups.
A further sensitivity analysis will be done by adjusting for severity of PPH (Table 5) and fibrinogen level or platelet count. This will be done using linear models (ANCOVA). 
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Influence of pregnancy diseases and PPH causes on the TXA effect for study outcomes In pregnant women diagnosed with preeclampsia, preterm labour and chorioamnionitis, was found an increased thrombin generation (Mastrolia et al., 2014) . Chaiworapongsa et al. (2002) also reported increased thrombin generation in patients diagnosed with preeclampsia and fetal growth restriction. Macey et al. (2010) comparing normal pregnancies with and without preeclampsia, reported an increased thrombin formation and increased platelet activation. Increased thrombin generation and platelet activity was found also in women with a history of preeclampsia (Rafik Hamad et al., 2009 ).
There is evidence that the haemostatic impairment that occurs in haemorrhage during pregnancy and delivery is different from trauma-induced haemorrhage. The type and rate of onset of coagulopathies differ depending on the main cause of obstetric haemorrhage (Collis & Collins, 2015) . Regarding haemostasis changes during obstetric haemorrhage, there is little data. The type, severity and rate of onset of the coagulopathy vary with the aetiology of bleeding.
Allard et al. (2014) raised the question, whether women with postpartum haemorrhage exhibit different changes from other patients who have haemorrhage during general surgery or trauma? Some of the underlying causes of postpartum haemorrhage such as uterine atony and genital tract trauma were often associated with no significant coagulopathy (Collins et al., 2014) . But, when the cause of PPH was placental abruption, it may be associated with rapid consumptive coagulopathy characterised with clinically severe haemostatic impairment (Thachil & Toh, 2009 ).
Influence of PPH severity, fibrinogen and platelet count on the TXA effect for study outcomes Low plasmatic level of fibrinogen such as 2 -3 g/L and especially less than 2 g/L at the beginning or on-going of PPH, was associated with an increased amount of blood loss, increased need for blood transfusion and requirements for invasive procedures. Low platelet number at the diagnosis of PPH was associated with the requirement for invasive procedures (Collins et al., 2014) . Simon et al. (1997) , observed an increased frequency of PPH, when in early labour platelet count is <100000/mm³ or fibrinogen level is <2.9mg/L or both. A study has reported that thrombocytopenia <80 000/mm³ was associated with an increased incidence of severe PPH (Dikman et al., 2014) , however, another study did not found any association between thrombocytopenia and severe PPH (Jones et al., 2016) .
A systematic review (Simonazzi et al., 2016) confirmed that TXA can significantly decrease the incidence of PPH with an amount of blood loss >500 ml and severe PPH with blood loss > 1000ml. Consume of coagulation factors and platelets were reported in cases with severe postpartum bleeding. The decrease of fibrinogen level, antithrombin activity, and the platelet count was observed in PPH cases with blood loss >2000 ml.
We will evaluate the effect of TXA/placebo on study outcomes (TGA, coagulation factors and platelet function tests), in cases with moderate PPH (500-1000ml) and severe PPH (>1000ml) ( Table 5 ).
The effect of TXA on study outcomes regarding the PPH severity will also be analysed regarding stratified amount of blood lost (500 mL, >500-1000 mL, >1000-1500 mL, or >1500 ml blood loss). Similar analysis will also be done for the effect of TXA on Figure 1 . Effect of TXA on TGA parameters, regarding the platelet count before randomization (graph model using arbitrary data).
thrombin generation and platelet function regarding complete blood count parameters such as baseline levels of haemoglobin (anaemia), platelets and their difference within 12 hours of randomization.
A series of graphs will present each TGA parameter (ETP, LT, TtP, Ph) as a panel of 4 boxplots which show the measured values for the treatment groups split with respect to baseline platelet count categorized as follows: <50000, 50000-100000, 100000-150000, ≥ 150000 (Figure 1) . Similar graphs will display the coagulation factors (FV, FVIII, vWF, fibrinogen and D-dimer) and Multiplatetests (ADPtest and TRAPtest) measured values, with respect to platelet count for both treatment groups. Differences between the TXA/placebo groups will be tested using the non-parametric Kruskall-Wallis test.
Baseline fibrinogen level and a panel of 7 dot-plots showing the corresponding individual measurements for each individual patient with respect to TGA-ETP, FV, FVIII, vWF, D-dimer, ADPtest and TRAPtest for both treatment groups TXA/placebo (Figure 2) .
The dots will be color-coded with respect to the treatment groups, a smoother will be presented in the corresponding colour, the Spearman correlation will be calculated and a 95% CI for each treatment group will be presented. Also, the difference between the correlation coefficients of the treatment groups will be calculated and a 95% confidence interval will be presented. The confidence intervals related to the Spearman correlation coefficient will be calculated by bootstraping.
Two panels of graphs will present the ADPtest parameters as well as the TRAPtest parameters. They will show individual measurements for aggregation, velocity, and AUC of TXA/placebo groups correlated with individual platelet count. These graphs (similar to Figure 2 ) will be produced for baseline, after treatment and change values.
Per-protocol analyses
All analyses as described in of the section 'Efficacy analysis for primary and secondary outcomes' will be repeated using the PP analysis set.
Secondary endpoints measured
The difference between study groups in absolute change between baseline and 30±15 minutes after study drug administration will be analysed in a descriptive manner. The comparison of the treatment groups for all secondary endpoints will be performed using a Mann-Whitney U test for quantitative measures and a chi-square test for frequencies. Continuous variables are expressed as mean±SD and stratified by treatment group, if normally distributed overall; otherwise these variables are expressed as median and IQR.
Conclusions
This article presents the principles of statistical analysis of the WOMAN ETAPlaT study, in order to ensure the credibility of the study findings by pre-specifying the statistical approaches to the analysis of the study data. The detailed SAP presented will help to prevent outcome bias, selective reporting and to avoid post hoc decisions that may influence the interpretation of the results and the statistical analyses of the final data. The data from this study will provide evidence for the effect of TXA on thrombin generation, platelet function and coagulation factors in women with PPH. This does not, therefore, appear to adjust for the baseline value (apart for the crude and inefficient adjustment through subtraction). On the other hand, there is an adjustment for the length of time between the two measurements. This implies that this length of time is itself considered to be predictive. That is to say it is supposed that two women given identical treatment would be expected to have different values of TGA according to the length of time it takes to measure TGA. This may well be reasonable (if some secular trend in TGA is expected) but in that case I would have expected some discussion of the point.
In short, I consider that the plan shows evidence of careful thought on the part of the authors but still leaves room for some doubt as regards the analysis. I must thus conclude that either the analysis proposed is not optimal or that the authors have failed to provide sufficient clarity to entirely convince at least one reader of its appropriateness. As far as I am aware I have no competing interests. However I was once involved Competing Interests: in designing a trial that used tranexamic acid (as a control treatment) in hereditary angioedema (HAE) and I have consulted for various companies on the subject of HAE. I maintain a full declaration of interest here: http://www.senns.demon.co.uk/Declaration_Interest.htm
